Navigation Links
Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
Date:8/19/2008

NEW HAVEN, Conn., Aug. 19 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Pink Sheets: VION) announced today that it had entered into an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (the "HOVON") to conduct a clinical trial of laromustine (Cloretazine(R) (VNP40101M)) with standard remission-induction therapy in patients aged 18-65 with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplasia (MDS).

Alan Kessman, Chief Executive Officer, commented, "We are pleased to be working with HOVON, one of the most prestigious clinical groups in hematology oncology. We continue to believe that Cloretazine(R) will have broad utility in the treatment of hematological malignancies as both a single agent and in combination with other therapies. This trial will provide important data with regard to Cloretazine(R)'s utility in the treatment of AML when given in combination with standard remission-induction therapy for this devastating disease."

Dr. Bob Lowenberg, Chief Investigator of HOVON, said, "HOVON is focusing on the clinical development of new therapeutic options for patients with leukemia. Laromustine is a promising agent for that effort."

The trial has been designed as a Phase III study in two parts. Part A will determine the feasibility (based on safety and preliminary effectiveness) of laromustine administration at three possible dose levels in combination with cytarabine and idarubicin. Part A will also evaluate the pharmacokinetics and the clinical efficacy of the laromustine combination.

Part B is then designed to evaluate the clinical efficacy of the laromustine combination versus two cycles of cytarabine and idarubicin without laromustine with regard to clinical outcome ("event free survival"), the complete remission rate, disease free survival (DFS), risk of relapse and overall survival (OS), as well as the tolerance and toxicity, and pharmacokinetics of the combin
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
3. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
6. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
7. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
8. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
10. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
11. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... support, China,s orthopedic instrument industry ... market size rising from 3.28 billion yuan in 2006 ...
(Date:1/15/2014)... 2014 As health officials across the Midwest warn against ... in Michigan will offer free diagnostic ... Meijer pharmacists to administer tests and, in some cases, fill ... participating in the study. The Grand ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
(Date:7/11/2014)... health officials have concluded that it,s highly unlikely any ... safety mishap last month. But, the U.S. Centers ... moratorium on the transfer of any dangerous germs or ... issued Friday, the CDC outlined several measures the agency ... occur again. Last month, as many as 75 workers ...
(Date:7/11/2014)... The report “Probiotics Market by Products ... Applications (Regular, Therapeutic, Preventive Health Care) & Ingredients ... to 2019 ” defines and segments the global ... the market value of probiotic products and ingredients. ... factors for the global market with an analysis ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
(Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
(Date:7/11/2014)... As reported by the New ... a significant number of severe adverse events such as ... even death from the highly-promoted and costly immune-system drug, ... report , a regulatory filing revealed that the ... was almost 14% of prescriptions, up from 9.1% in ...
Breaking Medicine News(10 mins):Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3
... effort to develop therapeutic remedies for multiple sclerosis, scientists ... opposite sides of the spectrum. Researchers at Wayne State ... conclusion as to which approach is correct, putting an ... Ph.D., associate professor of immunology and microbiology at WSU,s ...
... High-resolution images from a laser-based tool developed at Duke ... of skin cancer, while potentially saving thousands of lives and ... The tool probes skin cells using two lasers to pump ... pointer, into a suspicious mole. Scientists analyze the way the ...
... team of neuroscientists at Cold Spring Harbor Laboratory (CSHL), Brookhaven ... evidence suggesting that a previously overlooked portion of the brain ... In two rat models of human depression, the scientists ... central brain called the lateral habenula (LHb) are hyperactive. ...
... , WEDNESDAY, Feb. 23 (HealthDay News) -- ... bronchitis, a new study shows. U.S. researchers conducted ... and found that cigarette smoke suppresses a protein that ... airways of bronchitis patients. The study appears online ...
... Maureen Salamon HealthDay Reporter , WEDNESDAY, Feb. ... low back pain -- an increasingly controversial treatment that ... -- leads to higher rates of permanent disability for ... new study finds. Researchers randomly selected 725 people ...
... potentially improve survival from war injuries and disasters, laboratory ... shelf life well beyond the current standard of 24 ... blood retains its clotting properties at least 11 days ... M.D., a cardiothoracic anesthesiologist in the Cardiac Center at ...
Cached Medicine News:Health News:Wayne State University researchers publish results settling multiple sclerosis debate 2Health News:Lasers ID deadly skin cancer better than doctors 2Health News:Lasers ID deadly skin cancer better than doctors 3Health News:Neuroscientists find overlooked brain area is an important locus of depression 2Health News:Neuroscientists find overlooked brain area is an important locus of depression 3Health News:Cigarette Smoke Fuels Mucus Production in People With Bronchitis 2Health News:Spinal Fusion Surgery May Leave Some Back Pain Patients Worse Off: Study 2Health News:Spinal Fusion Surgery May Leave Some Back Pain Patients Worse Off: Study 3Health News:Whole fresh blood for transfusions may have a longer shelf life than now assumed 2
... the industry-leading portal to QC information, providing ... way to access their quality control data ... Internet. UnityWeb enables Bio-Rad customers to access ... as well as convenient online data entry ...
... self-adhesive insulin pod that you fill with insulin ... to three days and then replace. The OmniPod ... body through a small flexible tube (called a ... its wireless companion, the Personal Diabetes Manager. The ...
Inquire...
SPR treats pigmented and vascular lesions, skin aging, sun damaged skin and fine lines and wrinkles with clinically proven LHE technology....
Medicine Products: